Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2026-01-02 @ 1:19 PM
Study NCT ID:
NCT06048250
Status:
RECRUITING
Last Update Posted:
2025-05-01
First Post:
2023-09-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-09
Start Date Type:
ACTUAL
Primary Completion Date:
2026-03-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03-21
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-15
First Submit QC Date:
None
Study First Post Date:
2023-09-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-29
Last Update Post Date:
2025-05-01
Last Update Post Date Type:
ACTUAL